Claudio Pusceddu1, Luca Melis1, Nicola Ballicu1, Barbara Sotgia1, Marcovalerio Melis2, Valeria Sanna3, Giovanni Battista Meloni4, Alberto Porcu5, Alessandro Fancellu6. 1. Division of Interventional Radiology, Department of Oncological Radiology, Oncological Hospital A. Businco, Cagliari, Italy. 2. New York University School of Medicine and Department of Surgery, NY Harbor Healthcare System VAMC, New York, NY, USA. 3. Unit of Medical Oncology, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 4. Institute of Radiological Sciences, University of Sassari, Sassari, Italy. 5. Unit of General Surgery 2-Clinica Chirurgica, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 6. Unit of General Surgery 2-Clinica Chirurgica, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. afancel@uniss.it.
Abstract
BACKGROUND: Microwave ablation (MWA) is an emerging treatment for treatment of patients with hepatocellular carcinoma (HCC) not amenable of surgical resection. PATIENTS AND METHODS: We searched for patients diagnosed as having small-, medium-, and large HCCs treated with MWA under CT guidance between 2010 and 2014. The main outcomes of interest were rates of complete ablation, complications, and overall survival. Rates of complete ablation were compared with Chi-square test, and estimated survival rates were calculated by means of Kaplan-Meier method. RESULTS: Thirty-two patients with 45 HCC nodules received MWA. Seventeen (37.8%) nodules were <3 cm (small), 15 (33.3%) between 3 and 5 cm (medium), and 13 (28.9%) > 5 cm (large). Complete ablation was obtained in 94.1% of small tumors, 80% of medium tumors, and 53.8% of large tumors (p = 0.03). Two patients had HCC located in risk area (paracardiac position). Minor complications occurred after seven procedures (15.5%). Estimated median survival was 37 months (95% confidence interval 11.97-62.02). One-year OS was 82.7%, 2-year survival 68.9%, and 3-year survival 55.2%. CONCLUSION: MWA is a versatile ablative method that can be applied in HCC at various stages, and also in lesions located in risk areas.
BACKGROUND: Microwave ablation (MWA) is an emerging treatment for treatment of patients with hepatocellular carcinoma (HCC) not amenable of surgical resection. PATIENTS AND METHODS: We searched for patients diagnosed as having small-, medium-, and large HCCs treated with MWA under CT guidance between 2010 and 2014. The main outcomes of interest were rates of complete ablation, complications, and overall survival. Rates of complete ablation were compared with Chi-square test, and estimated survival rates were calculated by means of Kaplan-Meier method. RESULTS: Thirty-two patients with 45 HCC nodules received MWA. Seventeen (37.8%) nodules were <3 cm (small), 15 (33.3%) between 3 and 5 cm (medium), and 13 (28.9%) > 5 cm (large). Complete ablation was obtained in 94.1% of small tumors, 80% of medium tumors, and 53.8% of large tumors (p = 0.03). Two patients had HCC located in risk area (paracardiac position). Minor complications occurred after seven procedures (15.5%). Estimated median survival was 37 months (95% confidence interval 11.97-62.02). One-year OS was 82.7%, 2-year survival 68.9%, and 3-year survival 55.2%. CONCLUSION: MWA is a versatile ablative method that can be applied in HCC at various stages, and also in lesions located in risk areas.
Authors: Erica S Alexander; Farrah J Wolf; Jason T Machan; Kevin P Charpentier; Michael D Beland; Jason D Iannuccilli; Richard H Haas; Damian E Dupuy Journal: Eur J Radiol Date: 2015-03-14 Impact factor: 3.528
Authors: Oliver S Eng; Ashley T Tsang; Dirk Moore; Chunxia Chen; Sumana Narayanan; Christopher J Gannon; David A August; Darren R Carpizo; Laleh G Melstrom Journal: J Surg Oncol Date: 2014-12-29 Impact factor: 3.454